. 2020 Mar 6;7(3):229–239. doi: 10.1007/s40801-020-00183-x

Table 2.

Healthcare resource utilization during the post-index period

Healthcare resource utilization	Oral treprostinil	Selexipag	p value
Healthcare resource utilization	(N = 130)	(N = 126)	p value
All-cause healthcare resource utilization
Inpatient visits	43 (33.1)	29 (23.0)
Inpatient visits^a	0.4 ± 0.7	0.4 ± 0.9	0.127
Adjusted inpatient visits^b	1.3 ± 0.6	1.9 ± 0.8	0.199
Length of stay per hospitalization	5.8 ± 7.3	7.1 ± 7.4	0.297
Adjusted length of stay^b	8.6 ± 6.1	10.4 ± 7.3	0.441
Bed days^a	2.5 ± 6.4	2.8 ± 7.3	0.156
Outpatient visits
ED visits	33 (25.4)	32 (25.4)	0.998
ED visits^a	0.4 ± 1.1	0.4 ± 1.0	0.917
Overall outpatient visits	130 (100.0)	126 (100.0)	–
Overall outpatient visits^a	22.1 ± 16.6	18.7 ± 10.0	0.258
Adjusted overall outpatient visits^b	22.0 ± 8.4	18.8 ± 7.2	< 0.0001
Unique prescriptions	45 ± 20	49 ± 22	0.121
PAH-related healthcare resource utilization
Inpatient visits	10 (7.7)	5 (4.0)	0.205
Inpatient visits^a	0.1 ± 0.3	0.1 ± 0.3	0.211
Adjusted inpatient visits^b	1.2 ± 0.6	1.2 ± 0.6	1.000
Length of stay per hospitalization	4.0 ± 2.3	5.0 ± 6.3	0.673
Adjusted length of stay^b	1.2 ± 0.4	1.3 ± 0.4	0.397
Bed days^a	0.3 ± 1.4	0.3 ± 2.0	0.201
Outpatient visits
ED visits	3 (2.3)	0 (0.0)	0.086
ED visits^a	0.04 ± 0.3	0.0 ± 0.0	0.088
Overall outpatient visits	125 (96.2)	119 (94.4)	0.518
Overall outpatient visits^a	5.8 ± 4.8	5.4 ± 4.8	0.280
Adjusted overall outpatient visits^b	5.8 ± 2.17	6.0 ± 2.21	0.748
PAH-specific unique prescriptions	13.9 ± 6.4	14 ± 5.9	0.658

Data are presented as mean ± SD or N (%) unless otherwise indicated

ED emergency department, PAH pulmonary arterial hypertension, SD standard deviation

^aMean ± SD were calculated for the entire cohort

^bAdjusted for baseline age, sex, region, insurance plan type, prior prostacyclin use, presence of comorbid conditions, receipt of RHC and respective baseline pharmacy, inpatient, and total outpatient costs